NCT05564104View on ClinicalTrials.gov

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 5, 2023

Primary Completion Date

September 6, 2024

Study Completion Date

December 19, 2024

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

Cagrilintide

Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.

Trial Locations (3)

81241

APEX Research, München

83101

Summit Clinical Research s.r.o., Bratislava

901 22

Summit Clinical Research s.r.o., Malacky

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY